Abstract
A series of novel sorafenib derivatives containing diaryl thiourea and thioether, 9a–u, was designed and synthesized, and their antiproliferative activities against HCT116 and MDA-MB-231 cell lines were also evaluated and described. Most compounds exhibited potent antiproliferative activity against HCT116 cells with IC50 = 1.8–80.4 μM. Compounds 9p, 9r, and 9s demonstrated competitive antiproliferative activities to sorafenib, against all two cancer cell lines. The structures of all the newly synthesized compounds were determined by 1H NMR, 13C NMR, and HRMS, and compound 9n was characterized by single-crystal X-ray diffraction. Primary structure–activity relationships (SAR) have also been established.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Dai Y, Hartandi K, Ji Z, Ahmed AA, Albert DH, Bauch JL, Bouska JJ, Bousquet PF, Cunha GA, Glaser KB, Harris CM, Hickman D, Guo J, Li J, Marcotte PA, Marsh KC, Moskey MD, Martin RL, Olson AM, Osterling DJ, Pease LJ, Soni NB, Stewart KD, Stoll VS, Tapang P, Reuter DR, Davidsen SK, Michaelides MR (2007) Discovery of N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N’-(2-fluoro-5-methylphenyl)urea (ABT-869), a 3-aminoindazole-based orally active multitargeted receptor tyrosine kinase inhibitor. J Med Chem 50:1584–1597
Guida T, Anaganti S, Provitera L, Gedrich R, Sullivan E, Wilhelm SM, Santoro M, Carlomagno F (2007) Sorafenib inhibits imatinib-resistant KIT and platelet-derived growth factor receptor beta gatekeeper mutants. Clin Cancer Res 13:3363–3369
Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M, Carter C (2006) Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 66:11851–11858
Ménard D, Niculescu-Duvaz I, Dijkstra HP, Niculescu-Duvaz D, Suijkerbuijk BM, Zambon A, Nourry A, Roman E, Davies L, Manne HA, Friedlos F, Kirk R, Whittaker S, Gill A, Taylor RD, Marais R, Springer CJ (2009) Novel potent BRAF inhibitors: toward 1 nM compounds through optimization of the central phenyl ring. J Med Chem 52:3881–3891
Pauling L, Pauling P (1975) Chemistry. Freeman, San Francisco
Potashman MH, Bready J, Coxon A, DeMelfi TM Jr, DiPietro L, Doerr N, Elbaum D, Estrada J, Gallant P, Germain J, Gu Y, Harmange J-C, Kaufman SA, Kendall R, Kim JL, Kumar GN, Long AM, Neervannan S, Patel VF, Polverino A, Rose P, Van der Plas S, Whittington D, Zanon R, Zhao H (2007) Design, synthesis, and evaluation of orally active benzimidazoles and benzoxazoles as vascular endothelial growth factor-2 receptor tyrosine kinase inhibitors. J Med Chem 50:4351–4373
Ramurthy S, Subramanian S, Aikawa M, Amiri P, Costales A, Dove J, Fong S, Jansen JM, Levine B, Ma S, McBride CM, Michaelian J, Pick T, Poon DJ, Girish S, Shafer CM, Stuart D, Sung L, Renhowe PA (2008) Design and synthesis of orally bioavailable benzimidazoles as Raf kinase inhibitors. J Med Chem 51:7049–7052
Ravikumar K, Sridhar B, Bhujanga Rao AK, Pulla Reddy M (2011) Sorafenib and its tosylate salt: a multikinase inhibitor for treating cancer. Acta Crystallogr C 67:29–32
Sheldrick GM (1997) SHSLXL97, Program for Crystal Structure Refinement, University of Göttingen, Germany
Sun M, Wu X, Chen J, Cai J, Cao M, Ji M (2010) Design, synthesis, and in vitro antitumor evaluation of novel diaryl ureas derivatives. Eur J Med Chem 45:2299–2306
Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith RA, Schwartz B, Simantov R, Kelley S (2006) Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 5:835–844
Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M (2008) Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 7:3129–3140
Yao J, Chen J, He Z, Sun W, Xu W (2012) Design, synthesis and biological activities of thiourea containing sorafenib analogs as antitumor agents. Bioorg Med Chem 20:2923–2929
Acknowledgments
This study was supported by National Science and Technology Major Project (Grant No. 2009-ZX09103-118) and Ph.D. Programs Foundation of Ministry of Education of China (No. 20110131110037).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yao, J., Chen, J., He, Z. et al. Thiourea and thioether derivatives of sorafenib: synthesis, crystal structure, and antiproliferative activity. Med Chem Res 22, 3959–3968 (2013). https://doi.org/10.1007/s00044-012-0400-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00044-012-0400-8